Research programme: asthma therapeutics - TargepeuticsAlternative Names: TARG-ALLERG 1-200; TARG-ALLERG 1-201; TARG-ALLERG 1-202
Latest Information Update: 18 Jan 2011
At a glance
- Originator Targepeutics
- Mechanism of Action Interleukin 13 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Allergic asthma
Most Recent Events
- 05 Sep 2005 Preclinical trials in Allergic asthma in USA (Inhalation)
- 05 Sep 2005 Potential therpaeutics from this programme are available for licensing (http://www.targepeutics.com)